ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Evotec, Roche Join For Alzheimer’s Drug

by Rick Mullin
September 12, 2011 | APPEARED IN VOLUME 89, ISSUE 37

Evotec and Roche are partnering to develop Evotec’s EVT 302, an inhibitor of monoamine oxidase type B (MAO-B), as a treatment for Alzheimer’s disease. MAO-B is an enzyme that breaks down the chemical messenger dopamine in the brain, increasing production of free radicals that contribute to the disease. Under the agreement, Roche will pay Evotec an up-front fee of $10 million. Evotec could receive milestone payments of $820 million as well as royalties. The compound, soon to enter clinical trials, was initially licensed from Roche to Evotec in 2006 for another indication.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment